Literature DB >> 25291348

The Epidemiology of Cirrhosis in the United States: A Population-based Study.

Steven Scaglione1, Stephanie Kliethermes, Guichan Cao, David Shoham, Ramon Durazo, Amy Luke, Michael L Volk.   

Abstract

BACKGROUND AND AIMS: Liver cirrhosis is an important public health concern in the United States and a significant source of morbidity and mortality. However, the epidemiology of cirrhosis is incompletely understood. The aims of this study were to estimate the prevalence of cirrhosis in the general US population, determine characteristics of affected Americans with a focus on health disparities, and calculate excess mortality attributable to cirrhosis.
METHODS: National Health And Nutrition Examination Survey data conducted between 1999 and 2010 were used to estimate cirrhosis prevalence and factors associated with cirrhosis. The National Center for Health Statistics-linked death certificate data from the National Death Index were linked to the National Health And Nutrition Examination Survey database for the years 1999 to 2004, and attributable mortality was calculated using propensity score adjustment. Cirrhosis was ascertained by aspartate aminotransferase-to-platelet ratio of >2 and abnormal liver function tests.
RESULTS: The prevalence of cirrhosis in the United States was approximately 0.27%, corresponding to 633,323 adults. Sixty-nine percent reported that they were unaware of having liver disease. The prevalence was higher in non-Hispanic blacks and Mexican Americans, those living below the poverty level, and those with less than a 12th grade education. Diabetes, alcohol abuse, hepatitis C and B, male sex, and older age were all independently associated with cirrhosis, with a population attributable fraction of 53.5% from viral hepatitis (mostly hepatitis C), diabetes, and alcohol abuse. Mortality was 26.4% per 2-year interval in cirrhosis compared with 8.4% in propensity-matched controls.
CONCLUSIONS: The prevalence of cirrhosis is higher than previously estimated. Many cases may be undiagnosed, and more than half are potentially preventable by controlling diabetes, alcohol abuse, and viral hepatitis. Public health efforts are needed to reduce this disease burden, particularly among racial/ethnic minorities and individuals at lower socioeconomic status.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25291348     DOI: 10.1097/MCG.0000000000000208

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  202 in total

1.  Canadian regulations and legal ramifications for hepatic encephalopathy: a descriptive analysis.

Authors:  Henry H Nguyen; Mark G Swain; Philip Wong; Stephen E Congly
Journal:  CMAJ Open       Date:  2018-12-03

Review 2.  Current and Future Burden of Chronic Nonmalignant Liver Disease.

Authors:  Prowpanga Udompap; Donghee Kim; W Ray Kim
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-17       Impact factor: 11.382

3.  Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer.

Authors:  M Walker; H B El-Serag; Y Sada; S Mittal; J Ying; Z Duan; P Richardson; J A Davila; F Kanwal
Journal:  Aliment Pharmacol Ther       Date:  2016-01-19       Impact factor: 8.171

4.  Physicians' Perspectives on Palliative Care for Patients With End-Stage Liver Disease: A National Survey Study.

Authors:  Nneka N Ufere; John Donlan; Lauren Waldman; Arpan Patel; Jules L Dienstag; Lawrence S Friedman; Kathleen E Corey; Nikroo Hashemi; Peter Carolan; Alan C Mullen; Michael Thiim; Irun Bhan; Ryan Nipp; Joseph Greer; Jennifer Temel; Raymond T Chung; Areej El-Jawahri
Journal:  Liver Transpl       Date:  2019-05-03       Impact factor: 5.799

5.  Critically Ill Recipients of Weight-Based Fluconazole Meeting Drug-Induced Liver Injury Network Criteria.

Authors:  Merlyn Joseph; Rebecca Brady; Russell Attridge; Jason Cota; Cheryl Horlen; Kathleen Lusk; Rebecca L Attridge
Journal:  Hosp Pharm       Date:  2018-09-29

6.  Relationship between splenomegaly and transfusion requirements in patients with cirrhosis.

Authors:  Christopher H Tan; James A Hall; Kendall Hammonds; Jyothi Dodlapati; Walter J Linz; Sherronda M Henderson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-09-02

7.  Pre- and Peri-Operative Factors Associated with Chronic Critical Illness in Liver Transplant Recipients.

Authors:  Nicholas E Ingraham; Christopher J Tignanelli; Jeremiah Menk; Jeffrey G Chipman
Journal:  Surg Infect (Larchmt)       Date:  2019-10-16       Impact factor: 2.150

8.  Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.

Authors:  Mohammad Nasser Kabbany; Praveen Kumar Conjeevaram Selvakumar; Kymberly Watt; Rocio Lopez; Zade Akras; Nizar Zein; William Carey; Naim Alkhouri
Journal:  Am J Gastroenterol       Date:  2017-02-14       Impact factor: 10.864

9.  Exercise and physical activity in cirrhosis: opportunities or perils.

Authors:  Annette Bellar; Nicole Welch; Srinivasan Dasarathy
Journal:  J Appl Physiol (1985)       Date:  2020-04-02

10.  Association between interleukin-10 gene promoter polymorphisms and susceptibility to liver cirrhosis.

Authors:  Lanjie Yao; Shuli Xing; Xueqin Fu; Hongjie Song; Zhendong Wang; Jianrong Tang; Yongjing Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.